Treatment-related osteoporosis in men with prostate cancer
- 31 Downloads
Osteoporosis is an important complication of androgen-deprivation therapy (ADT) for prostate cancer. ADT by either bilateral orchiectomies or treatment with a gonadotropin-releasing hormone (GnRH) agonist decreases bone mineral density (BMD) and increases the risk of fracture. Prospective data about treatment or prevention of osteoporosis in men with prostate cancer are limited. Supplemental calcium and vitamin D are recommended. Additional therapy may be warranted for men with osteoporosis or fractures. Intravenous pamidronate prevents bone loss in the hip and spine during ADT. Intravenous zoledronic acid not only prevents bone loss but also increases BMD. Alendronate is approved to treatmen with osteoporosis although the efficacy of alendronate or other oral bisphosphonates has not been evaluated during ADT. Additional prospective studies are needed to evaluate the long-term effects of bisphosphonates and other the rapies on fracture risk and disease-related outcomes.
Key WordsBone osteoporosis prostate cancer gonadotropin-releasing hormone agonist antiandrogen
Unable to display preview. Download preview PDF.
- 2.Anonymous 1997 Immediate versus deferred treatment for advanced prostatic cancer; initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 79:235-246.Google Scholar
- 5.Moul JW 1998 Contemporary hormonal management of advanced prostate cancer. Oncology (Huntingt) 12:499–505; discussion 506-508.Google Scholar
- 7.1999 Agency for Health Care Policy and Research. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Summary, evidence report/technology assessment: No. 4. Available from: http://ahrq.gov/clinic/prossumm.htmGoogle Scholar
- 19.Berruti A, Dogliotti L, Terrone C, et al. 2002 Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol 167:2361–2367; discussion 2367.PubMedCrossRefGoogle Scholar
- 20.Diamond T, Campbell J, Bryant C, Lynch W 1998 The effect of combined androgen blockade on bone turnover and bone mineral densities in men treatment for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer 83:1561–1566.PubMedCrossRefGoogle Scholar